September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Update on uveitis in Ebola virus disease survivors, presented by the 2016 Ludwig von Sallmann Clinician-Scientist Award Recipient
Author Affiliations & Notes
  • Steven Yeh
    Emory Eye Center, Atlanta, Georgia, United States
  • Footnotes
    Commercial Relationships   Steven Yeh, Bausch and Lomb (C), Clearside Biomedical (C), Santen (C)
  • Footnotes
    Support  Research to Prevent Blindness Unrestricted Grant to the Emory Eye Center; NIH P30 EY006360 - P30 - Core Grant for Vision Research
Investigative Ophthalmology & Visual Science September 2016, Vol.57, No Pagination Specified. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Steven Yeh; Update on uveitis in Ebola virus disease survivors, presented by the 2016 Ludwig von Sallmann Clinician-Scientist Award Recipient. Invest. Ophthalmol. Vis. Sci. 201657(12):.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Presentation Description : The most recent Ebola virus disease (EVD) outbreak in West Africa is the largest outbreak in history with over 28,000 persons infected and over 11,000 deaths. The case fatality rate ranges between 57-60% in the three highest transmission countries - Sierra Leone, Liberia, and Guinea. The magnitude of the outbreak has led to the largest EVD survivor cohort in history, many of whom are at risk for the post Ebola syndrome, a constellation of disease findings including arthritis/arthralgias, fatigue, psychosocial stress, and uveitis. Prior reports of uveitis in EVD survivors are limited although a spectrum of uveitis (anterior and posterior uveitis) has been reported in limited case series. One recent EVD survivor developed severe, sight-threatening panuveitis and required intensive medical treatment to avert severe vision impairment and blindness. During his care, the patient was found to harbor live, replicating Ebola virus in his aqueous humor in a high concentration, which likely contributed to the disease pathogenesis. Our patient's findings had ramifications from individual, public and global health perspectives. Recent World Health Organization estimates have described ocular symptoms in up to 40-50% of EVD survivors and uveitis is estimated to occur in approximately 20-25% of EVD survivors although the precise incidence and prevalence remain unknown. The approach to evaluation and treatment of EVD survivors in a resource-limited, post EVD outbreak setting, clinical manifestations, and ongoing work by the World Health Organization, Ministry of Health and Sanitation of countries in West Africa, and partnering organizations will be discussed and a comprehensive update on EVD-associated uveitis will be provided.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.